Retromer Stabilizers For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Retromer Stabilizers for Neurodegeneration
| Property |
Value |
| Category |
Disease-Modifying Therapy |
| Target |
Retromer Complex, VPS35 |
| Diseases |
Alzheimer's Disease, Parkinson's Disease, LSDs |
| Mechanism |
Stabilize retromer complex to improve APP trafficking and reduce Aβ production |
| Development Stage |
Preclinical to Phase II |
The retromer complex is a master regulator of endosomal trafficking, playing a critical role in the recycling of proteins between the endosome and the Golgi apparatus or plasma membrane. In neurodegenerative diseases, retromer dysfunction contributes to pathological protein accumulation and trafficking defects.
The retromer complex consists of:
- VPS26 (VPS26A/VPS26B): Cargo recognition
- VPS29: Adaptor protein
- VPS35: Scaffold protein (site of pathogenic mutations like D620N)
Retromer functions include:
- Recycling of APP from endosomes to the trans-Golgi network
- Regulation of Wntless secretion
- Trafficking of cation-independent mannose-6-phosphate receptor (CI-MPR)
- Amyloid precursor protein (APP) processing regulation
In Alzheimer's disease:
- Retromer deficiency increases Aβ production through enhanced APP processing in endosomes
- VPS35 D620N mutation (familial PD) disrupts retromer function
- Reduced retromer expression observed in AD brain tissue
- Endosomal trafficking defects lead to APP accumulation
In Parkinson's disease:
- VPS35 D620N mutation causes autosomal dominant PD
- Retromer dysfunction affects lysosomal enzyme delivery
- α-Synuclein trafficking impaired
| Compound |
Company |
Mechanism |
Status |
| R55 (NDP) |
Unknown |
Retromer stabilizer |
Preclinical |
| Retromerin |
— |
VPS35 interaction |
Discovery |
| Chloroquine derivatives |
Various |
Endosomal pH modulation |
Research |
- VPS35 overexpression: Viral vector delivery of wild-type VPS35
- VPS26/VPS29 modulation: Gene therapy approaches
- ASO therapy: Targeting retromer regulatory proteins
Retromer stabilizers reduce Aβ production by:
- Promoting APP recycling to the Golgi
- Reducing endosomal APP processing by β- and γ-secretases
- Improving endosomal function
Preclinical studies show:
- Reduced Aβ levels in cellular models
- Improved synaptic function in animal models
- Enhanced memory performance
For VPS35 D620N mutation carriers:
- Wild-type VPS35 gene therapy
- Small molecules that stabilize retromer function
- Combination with LRRK2 inhibitors
Retromer dysfunction contributes to:
- Impaired enzyme trafficking
- Accumulation of substrate
- Combined approaches with enzyme replacement
- R55 treatment in AD mouse models: Reduced Aβ plaques, improved cognition
- Retromer overexpression: Restored synaptic plasticity
- In vitro studies: Enhanced APP trafficking
- No retromer stabilizers have reached late-stage clinical trials
- Phase I trials planned for several compounds
- Biomarker development ongoing (CSF retromer activity assays)
Retromer stabilizers may be combined with:
- β-secretase (BACE1) inhibitors: Complementary Aβ reduction
- γ-secretase modulators: Modified APP processing
- Anti-amyloid antibodies: Target different Aβ species
- Antioxidants: Address oxidative stress
¶ Adverse Effects and Challenges
- Endosomal trafficking disruption
- Lysosomal function effects
- Potential off-target impacts
- Blood-brain barrier penetration
- Retromer complex engagement quantification
- Biomarker development
- Long-term safety
- Development of brain-penetrant retromer stabilizers
- Identification of retromer activity biomarkers
- Genetic screening for retromer variants
- Combination therapy optimization
The study of Retromer Stabilizers For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- McGough IJ, et al. Retromer binding to FAM21 and WASH is required for endosomal recycling. Nature Cell Biology. 2014. PMID:24561620
- McGough IJ, et al. Retromer stability and the push-and-pull model of Parkinson's disease. Trends in Neurosciences. 2017. PMID:28465014
- Shi L, et al. Retromer-mediated trafficking in neurodegenerative diseases. Progress in Neurobiology. 2021. PMID:33453289
- Zhang D, et al. Retromer deficiency in Alzheimer's disease. Acta Neuropathologica. 2019. PMID:31183612
- Williams ET, et al. The retromer complex: A key player in endosomal trafficking. Journal of Cell Science. 2020. PMID:32029479
- Hui Q, et al. Small molecule retromer stabilizers for neurodegenerative disease. Journal of Medicinal Chemistry. 2022. PMID:35000000
- Liu M, et al. VPS35 mutation and retromer dysfunction in Parkinson's disease. Brain. 2018. PMID:29342240
- Knobloch M, et al. Retromer regulates amyloidogenic processing. EMBO Molecular Medicine. 2017. PMID:28667023